

Jennifer Cautela

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7796000/jennifer-cautela-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

539
citations

11
h-index

23
g-index

25
ext. papers

811
ext. citations

5.6
avg. IF

3.43
L-index

#	Paper	IF	Citations
24	Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis.. <i>Radiology</i> , 2022 , 211765	20.5	2
23	Cancer Therapies and Vascular Toxicities.. <i>Current Treatment Options in Oncology</i> , 2022 , 23, 333	5.4	0
22	Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 312-320	6.4	17
21	Rational and Design of the SIMULATOR Study: A Multicentre Randomized Study to Assess the Impact of SIMULATION-bAsed Training on Transoesophageal echocardiOgraphy leaRning for Cardiology Residents. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 661355	5.4	0
20	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. <i>JAMA Cardiology</i> , 2021 , 6, 1329-1337	16.2	12
19	Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 476-481	3.8	16
18	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. <i>Journal of the American Heart Association</i> , 2020 , 9, e018403	6	44
17	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis 2020 , 8,		14
16	Dynamic iron status after acute heart failure. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 410-419	2.7	5
15	Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. <i>European Journal of Internal Medicine</i> , 2019 , 68, 71-75	3.9	8
14	Device-Related Thrombus After Left Atrial Appendage Occlusion With the Amulet Device. <i>Heart Lung and Circulation</i> , 2019 , 28, 1683-1688	1.8	3
13	Impact of the time-to-treatment concept on the outcome of acute heart failure: A pilot study. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 270-275	2.7	2
12	Response to the letter: The high burden of coronary artery disease in heart failure with preserved ejection fraction. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 227	2.7	1
11	Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>JACC: Cardiovascular Imaging</i> , 2018 , 11, 1187-1190	8.4	55
10	Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 109-118	2.7	13
9	Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention. <i>Heart Lung and Circulation</i> , 2018 , 27, 984-988	1.8	4
8	Response by Thuny et al to Letter Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , 2018 , 137, 2423-2424	16.7	

7	Controlled sedation with midazolam and analgesia with nalbuphine to alleviate pain in patients undergoing subcutaneous implantable cardioverter defibrillator implantation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017 , 49, 191-196	2.4	11
6	Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. <i>International Journal of Cardiology</i> , 2017 , 241, 387-392	3.2	21
5	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017 , 136, 2085-2087	16.7	230
4	Prehospital and in-hospital course of care for patients with acute heart failure: Features and impact on prognosis in "real life". <i>Archives of Cardiovascular Diseases</i> , 2017 , 110, 72-81	2.7	4
3	Wearable cardioverter defibrillator: Bridge or alternative to implantation?. <i>World Journal of Cardiology</i> , 2017 , 9, 531-538	2.1	9
2	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. <i>International Journal of Cardiology</i> , 2016 , 224, 366-375	3.2	19
1	Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. <i>American Journal of Medicine</i> , 2015 , 128, 784.e1-8	2.4	45